Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

References

• Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669–15. doi:10.1073/pnas.1108455108.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11):4005–10. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Wilkinson I, Hale G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022;14(1):2123299. doi:10.1080/19420862.2022.2123299.
   PubMed Web of Science ®Google Scholar
• Chen X, Song X, Li K, Zhang T. FcgammaR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front Immunol. 2019;10:292. doi:10.3389/fimmu.2019.00292.
   PubMed Web of Science ®Google Scholar
• Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat Biotechnol. 2020;38(7):789–91. doi:10.1038/s41587-020-0577-1.
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Gao C, Shirinian L, Wu H, Dall’Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr. 2008;64(6):700–04. doi:10.1107/S0907444908007877.
   PubMedGoogle Scholar
• Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJ, et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. 2017;292(9):3900–08. doi:10.1074/jbc.M116.767749.
   PubMed Web of Science ®Google Scholar
• Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989;143:2595–601.
   PubMed Web of Science ®Google Scholar
• Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, Pedley B, Adair JR. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30(1):105–08. doi:10.1016/0161-5890(93)90432-B.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganesyan V, Dall’Acqua WF, Tsui P. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem. 2015;290(7):4282–90. doi:10.1074/jbc.M114.603712.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514–24. doi:10.1074/jbc.M604292200.
   PubMed Web of Science ®Google Scholar
• Lee CH, Kang TH, Godon O, Watanabe M, Delidakis G, Gillis CM, Sterlin D, Hardy D, Cogne M, Macdonald LE, et al. An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. Nat Commun. 2019;10(1):5031. doi:10.1038/s41467-019-13108-2.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3(5):422–30. doi:10.4161/mabs.3.5.16983.
   PubMed Web of Science ®Google Scholar
• Majumdar R, Esfandiary R, Bishop SM, Samra HS, Middaugh CR, Volkin DB, Weis DD. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. MAbs. 2015;7(1):84–95. doi:10.4161/19420862.2014.985494.
   PubMed Web of Science ®Google Scholar
• Thakkar SV, Sahni N, Joshi SB, Kerwin BA, He F, Volkin DB, Middaugh CR. Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies. Protein Sci. 2013;22(10):1295–305. doi:10.1002/pro.2316.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–49. doi:10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64. doi:10.1080/19420862.2018.1553476.
   PubMed Web of Science ®Google Scholar
• Starr CG, Tessier PM. Selecting and engineering monoclonal antibodies with drug-like specificity. Curr Opin Biotechnol. 2019;60:119–27. doi:10.1016/j.copbio.2019.01.008.
   PubMed Web of Science ®Google Scholar
• Yadav S, Liu J, Shire SJ, Kalonia DS. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci. 2010;99(3):1152–68. doi:10.1002/jps.21898.
   PubMed Web of Science ®Google Scholar
• Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J. 2012;103(1):69–78. doi:10.1016/j.bpj.2012.04.047.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs. 2015;7(6):1084–93. doi:10.1080/19420862.2015.1075109.
   PubMed Web of Science ®Google Scholar
• Hotzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4(6):753–60. doi:10.4161/mabs.22189.
   PubMed Web of Science ®Google Scholar
• Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL Jr. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 2008;47(18):5088–100. doi:10.1021/bi702238b.
   PubMed Web of Science ®Google Scholar
• Mo J, Yan Q, So CK, Soden T, Lewis MJ, Hu P. Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2016;88(19):9495–502. doi:10.1021/acs.analchem.6b01958.
   PubMed Web of Science ®Google Scholar
• Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol. 2011;48(6–7):860–66. doi:10.1016/j.molimm.2010.12.009.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain Individuals. December 8, 2021 press release [accessed September 18, 2022]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure.
   Google Scholar
• Medicines and Healthcare products Regulatory Agency. Evusheld approved to prevent COVID-19 in people whose immune response is poor. 17 March, 2022 press release [accessed September 18, 2022]. https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor.
   Google Scholar
• Health Canada. Health Canada authorizes Evusheld for the prevention of COVID-19 in immune compromised adults and children. April. 2022; 14. press release accessed September 18, 2022. https://www.canada.ca/en/health-canada/news/2022/04/health-canada-authorizes-evusheld-for-the-prevention-of-covid-19-in-immune-compromised-adults-and-children.html
   Google Scholar
• European Medicines Agency. EMA recommends authorisation of COVID-19 medicine Evusheld. March 24, 2022 press release [accessed September 18, 2022]. https://www.ema.europa.eu/en/news/ema-recommends-authorisation-covid-19-medicine-evusheld
   Google Scholar
• Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, Kim K, Campos JAS, Arends RH, Brodek BH, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985–96. doi:10.1016/S2213-2600(22)00180-1.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386(23):2188–200. doi:10.1056/NEJMoa2116620.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Mody N, Lu X, Kuhn ML, Wu H, Dall’Acqua WF, Tsui P. An “Fc-silenced” IgG1 format with extended half-life designed for improved stability. J Pharm Sci. 2017;106(4):1008–17. doi:10.1016/j.xphs.2016.12.023.
   PubMed Web of Science ®Google Scholar
• Edgeworth MJ, Phillips JJ, Lowe DC, Kippen AD, Higazi DR, Scrivens JH. Global and local conformation of human IgG antibody variants rationalizes loss of thermodynamic stability. Angew Chem Int Ed Engl. 2015;54(50):15156–59. doi:10.1002/anie.201507223.
   PubMed Web of Science ®Google Scholar
• Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. MAbs. 2011;3(3):253–63. doi:10.4161/mabs.3.3.15608.
   PubMed Web of Science ®Google Scholar
• Cordoba AJ, Shyong BJ, Breen D, Harris RJ. Non-enzymatic hinge region fragmentation of antibodies in solution. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;818(2):115–21. doi:10.1016/j.jchromb.2004.12.033.
   PubMed Web of Science ®Google Scholar
• Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, McGreevy W, Zheng K, Kelley RF, Laird MW, Liu J, et al. Effect of individual Fc methionine oxidation on FcRn binding: met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. J Pharm Sci. 2015;104(2):368–77. doi:10.1002/jps.24136.
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296. doi:10.3389/fimmu.2019.01296.
   PubMed Web of Science ®Google Scholar
• Gunn BM, Lu R, Slein MD, Ilinykh PA, Huang K, Atyeo C, Schendel SL, Kim J, Cain C, Roy V, et al. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity. 2021;54(4):815–28 e5. doi:10.1016/j.immuni.2021.03.009.
   PubMed Web of Science ®Google Scholar
• The antibody society. Antibody therapeutics approved or in regulatory review in the EU or US. Webpage updated September 2 2022 [accessed September 18, 2022]. https://www.antibodysociety.org/resources/approved-antibodies/.
   Google Scholar
• Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53. doi:10.1128/AAC.01285-13.
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall’acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol. 2009;46(8–9):1750–55. doi:10.1016/j.molimm.2009.01.026.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. February. 2018; 16. press release accessed September 18, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc
   Google Scholar
• US Food and Drug Administration. Novel Drug Approvals for 2021. May 13 2022 press release [accessed September 18, 2022]. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021.
   Google Scholar
• European Medicines Agency. Meeting highlights from the committee for medicinal products for human use (CHMP) 12-15 September 2022. September 16 2022 press release [accessed September 18 2022]. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022.
   Google Scholar
• Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett. 2002;82(1–2):57–65. doi:10.1016/S0165-2478(02)00019-6.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol. 2000;37(12–13):697–706. doi:10.1016/S0161-5890(00)00105-X.
   PubMed Web of Science ®Google Scholar
• Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs. 2011;3(6):568–76. doi:10.4161/mabs.3.6.17922.
   PubMed Web of Science ®Google Scholar
• Eskandary F, Durr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, et al. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 2019;20(1):37. doi:10.1186/s13063-018-3158-6.
   PubMedGoogle Scholar
• Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71(7):1183–89. doi:10.1136/annrheumdis-2011-200704.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol. 2016;68(9):2163–73. doi:10.1002/art.39700.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Tecentriq EPAR. September 29, 2017 press release [accessed September 18, 2022]. https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves new, targeted treatment for bladder cancer. May 18, 2016 press release [accessed September 18, 2022]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-bladder-cancer.
   Google Scholar
• US Food and Drug Administration. FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma. July 30, 2020 press release [accessed September 18, 2022]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma.
   Google Scholar
• US Food and Drug Administration. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. May 29, 2020 press release [accessed September 18, 2022]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma.
   Google Scholar
• US Food and Drug Administration. FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression. May 18, 2020 press release [accessed September 18, 2022]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression.
   Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–59. doi:10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Booth BJ, Ramakrishnan B, Narayan K, Wollacott AM, Babcock GJ, Shriver Z, Viswanathan K. Extending human IgG half-life using structure-guided design. MAbs. 2018;10(7):1098–110. doi:10.1080/19420862.2018.1490119.
   PubMed Web of Science ®Google Scholar
• Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, et al. Predicting antibody developability profiles through early stage discovery screening. MAbs. 2020;12(1):1743053. doi:10.1080/19420862.2020.1743053.
   PubMed Web of Science ®Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. 2014;6(2):483–92. doi:10.4161/mabs.27431.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Saini A, Auclair SM, Fu L, Lantz MM, Halloran KT, Calero-Rubio C, Schwenger W, Airiau CY, Zhang J, et al. A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv. 2020;6(32):eabb0372. doi:10.1126/sciadv.abb0372.
   PubMed Web of Science ®Google Scholar
• Loo YM, McTamney PM, Arends RH, Abram ME, Aksyuk AA, Diallo S, Flores DJ, Kelly EJ, Ren K, Roque R, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Sci Transl Med. 2022:eabl8124.
   Google Scholar
• Yan Q, Huang M, Lewis MJ, Hu P. Structure based prediction of asparagine deamidation propensity in monoclonal antibodies. MAbs. 2018;10(6):901–12. doi:10.1080/19420862.2018.1478646.
   PubMed Web of Science ®Google Scholar
• Lu X, Nobrega RP, Lynaugh H, Jain T, Barlow K, Boland T, Sivasubramanian A, Vasquez M, Xu Y. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs. 2019;11(1):45–57. doi:10.1080/19420862.2018.1548233.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55. doi:10.1080/19420862.2017.1417718.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. MAbs. 2015;7(3):483–93. doi:10.1080/19420862.2015.1016696.
   PubMed Web of Science ®Google Scholar
• Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15–32. doi:10.1007/s13238-017-0408-4.
   PubMed Web of Science ®Google Scholar
• Webster CI, Hatcher J, Burrell M, Thom G, Thornton P, Gurrell I, Chessell I. Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity. Pain. 2017;158(4):660–68. doi:10.1097/j.pain.0000000000000810.
   PubMed Web of Science ®Google Scholar
• Geng SB, Wu J, Alam ME, Schultz JS, Dickinson CD, Seminer CR, Tessier PM. Facile preparation of stable antibody-gold conjugates and application to affinity-capture self-interaction nanoparticle spectroscopy. Bioconjug Chem. 2016;27(10):2287–300. doi:10.1021/acs.bioconjchem.6b00207.
   PubMed Web of Science ®Google Scholar